5-Amino-1MQ
5-Amino-1MQ scored 4.3 / 10 (⚠️ Caution) on the BioHarmony scale as a Substance → Research Compound.
5-Amino-1MQ is a synthetic NNMT-inhibitor research compound that cut fat mass in obese mice and raised NAD+ in cultured fat cells (Neelakantan 2018), but it has zero human trials. Oral 50 to 150 mg is the only route with pharmacokinetic support; injectable microgram doses are likely too low to work.
What is 5-Amino-1MQ?
5-Amino-1MQ is a synthetic small molecule that blocks an enzyme called NNMT (nicotinamide N-methyltransferase), which in animal studies frees up raw material for NAD+ and helps mice lose fat (Neelakantan 2018) and rebuild aging muscle (Neelakantan 2019). It is marketed for fat loss, muscle and strength, energy, and longevity, and sold as a research compound rather than an approved drug or supplement. It has never been tested in a single human trial. Oral dosing of 50 to 150 mg is the only route with pharmacokinetic support, while the popular injectable microgram protocols are almost certainly too low to do anything. The Caution score reflects that gap: the mechanism is well grounded and the mouse data look genuinely interesting, but there is no clinical evidence, the grey-market supply chain has no quality oversight, and the heavily marketed longevity angle rests on shaky mechanistic ground.
Despite often being sold next to peptides, 5-Amino-1MQ is not a peptide. It is a small, well-absorbed molecule, which is why it works orally and why injecting tiny microgram doses tends to do nothing. NNMT normally burns through nicotinamide and methyl groups; by slowing that enzyme, 5-Amino-1MQ spares both, which is the basis for its proposed effects on fat, muscle, and metabolism (Kraus 2014, Pissios 2017). I came to it through a podcast conversation with longevity researcher Ryan Smith, and it is one of the few compounds in this category I actually feel.
Terminology
5-Amino-1MQ sits at the intersection of NAD+ biology and methylation chemistry, so a handful of terms decide how you read the evidence. The most important distinction is that 5-Amino-1MQ acts on an enzyme (NNMT) rather than on a receptor, which is why it needs milligram, not microgram, dosing to work. Two other distinctions matter just as much: almost everything known about the compound comes from animals rather than people, so the word preclinical appears throughout, and the metabolite NNMT produces (1-MNA) is biologically active in its own right rather than simply waste. Getting these terms straight is what separates a fair read of 5-Amino-1MQ from the inflated marketing version that surrounds it. Here are the terms used throughout this report, each defined in plain language.
- NNMT: Nicotinamide N-methyltransferase. The enzyme 5-Amino-1MQ blocks. When overactive, it drains the cell of NAD+ precursors and methyl groups.
- NAD+: Nicotinamide adenine dinucleotide. A molecule every cell needs to make energy and run repair enzymes. NNMT activity lowers it; blocking NNMT helps preserve it.
- SAM: S-adenosylmethionine. The body's main methyl-group donor. NNMT consumes SAM, so inhibiting NNMT spares it.
- 1-MNA: 1-methylnicotinamide. The byproduct NNMT makes. Often called waste, but it has real biological activity (see Downside Rationale).
- Preclinical: Evidence from cells or animals only, with no human studies.
- DIO: Diet-induced obesity. The mouse model used in most 5-Amino-1MQ fat-loss studies.
- Bioavailability: The fraction of an oral dose that reaches the bloodstream. For 5-Amino-1MQ it is about 38% in rats.
- Half-life: How long it takes the body to clear half a dose. About 6.9 hours orally in rats.
- Subcutaneous: An injection into the fat layer under the skin.
- WADA S0: A World Anti-Doping Agency category for substances not approved by any regulator for human use. 5-Amino-1MQ falls here and is banned in sport.
How do you take 5-Amino-1MQ?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule or tablet (commonly 50 mg) | None established (no human trials) | 50 to 150 mg per day |
| Subcutaneous injection | Reconstituted vial (5 to 50 mg) | None | 150 mcg to 100 mg per day (40-fold community spread) |
Protocols
Oral pre-workout (anecdotal) Anecdotal
- Dose
- 50 to 100 mg
- Frequency
- Once daily, morning
- Duration
- 4 to 8 week cycles
Nick's pattern. Often stacked with other pre-workout compounds. Energy felt about 30 minutes after dosing.
Oral titration (anecdotal) Anecdotal
- Dose
- Start 50 mg, titrate to 150 mg
- Frequency
- Daily, sometimes split AM and midday
- Duration
- 4 to 8 weeks, then a 1 to 2 week break
Split dosing is common because the half-life is short. Higher doses raise the odds of insomnia.
How this score is calculated →
What are the benefits of 5-Amino-1MQ?
Upside contribution: 1.66
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.0 | 0.750 | |
| Breadth | 15% | 3.2 | 0.480 | |
| Evidence | 25% | 1.8 | 0.450 | |
| Speed | 10% | 3.5 | 0.350 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality | 15% | 2.5 | 0.375 | |
| Total | 2.655 |
Upside Rationale
The upside of 5-Amino-1MQ comes almost entirely from fat loss and muscle data in mice, plus a solid mechanism, and it is held back hard by the complete absence of human evidence. The single strongest finding is that obese mice lost roughly 5% of body weight with over 30% smaller fat cells (Neelakantan 2018). The benefit ceiling is real but narrow: muscle gains showed up only in aged, injured animals, the metabolic data lean on related compounds rather than 5-Amino-1MQ itself, and nobody has run a human study. The most reliable real-world upside is the fast energy lift users feel within an hour of an oral dose, which is also the effect with the least hard data behind it. Treat the upside as a promising preclinical signal, not a proven human effect.
Efficacy (3.0/5.0): In obese mice, 5-Amino-1MQ produced roughly 5% body-weight loss with over 30% smaller fat cells, an effect driven by increased fat burning rather than reduced appetite (Neelakantan 2018). In aged mice, it nearly doubled muscle-fiber size and raised peak torque after injury (Neelakantan 2019), and a separate aged-mouse study found about 40% higher grip strength (Dimet-Wiley 2024). These are moderate-to-large animal effects. The problem for efficacy is twofold: every positive study used subcutaneous injection in rodents, while humans take it orally, and the muscle benefit appeared only in aged or injured animals, so it may not transfer to a young, healthy user. With zero human trials, efficacy in people remains unproven, which is why this score lands in the middle rather than higher.
Breadth of Benefits (3.2/5.0): 5-Amino-1MQ acts on an upstream hub, NNMT, that touches several systems, which gives it real mechanistic breadth. Documented animal endpoints span fat tissue (smaller fat cells, lower body weight), skeletal muscle (regeneration and strength in aged mice), and metabolism (glucose tolerance, mostly via related inhibitors like JBSNF-000088, Kannt 2018). Newer reviews extend the target to fibrosis and senescence (Puleo 2026, Sun 2024). The boundary is that proven breadth is far narrower than mechanistic breadth: outside fat and aged muscle, most claimed uses rest on theory or on data from other NNMT inhibitors, not 5-Amino-1MQ.
Evidence Quality (1.8/5.0): This is the dimension that defines the score, and it sits near the floor because there is no human evidence at all. ClinicalTrials.gov lists zero registered trials of 5-Amino-1MQ or any NNMT inhibitor, and there are no meta-analyses. The in-vivo efficacy literature is a handful of mouse studies, most from a single research group, which limits independent replication. The mechanism itself is strong, supported by a Nature knockdown study (Kraus 2014) and independent cancer-biology work (Eckert 2019). Strong mechanism plus reproducible animal data, but no human trials, places this at preclinical tier and no higher.
Speed of Onset (3.5/5.0): The felt effect is fast. Most users, including Nick, report a clear energy lift within 30 to 90 minutes of an oral dose, which fits the short pharmacokinetic profile of about a 6.9 hour half-life (Awosemo 2021). Body-composition changes are slower, reported over 4 to 8 weeks in community use, and in mice fat and muscle effects emerged over 1 to 3 weeks of dosing. The split matters: the stimulation arrives quickly, while the metabolic payoff, if it comes, takes weeks.
Durability (2.5/5.0): Durability is a weak point for 5-Amino-1MQ. Animal benefits held during dosing, but no study has measured whether they persist after stopping, and community reports describe effects fading after about 4 to 6 weeks, which is why most people cycle. There is no evidence the changes are self-sustaining, so any benefit appears to require ongoing dosing. Without washout data, the safe read is that this is a maintained-while-using effect, not a durable one.
Bioindividuality Upside (2.5/5.0): Response to 5-Amino-1MQ varies widely, which lowers this score rather than raising it. Community reports split sharply between people who feel strong energy and fat loss and people who feel nothing, with leaner users on a calorie deficit reporting the best results. Some of that variance is dosing confusion (microgram injections that never reach an active dose), but some is genuine individual difference. No human biomarker or genetic predictor of response exists, so there is no reliable way to know in advance whether a given person will respond.
What are the risks & downsides of 5-Amino-1MQ?
Downside contribution: 2.43 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 3.3 | 0.990 | |
| Side effects | 15% | 3.0 | 0.450 | |
| Cost | 5% | 3.7 | 0.185 | |
| Effort | 5% | 2.5 | 0.125 | |
| Opportunity | 5% | 3.0 | 0.150 | |
| Dependency | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 2.2 | 0.550 | |
| Total | 2.825 | |||
| Harm subtotal × 1.4 | 3.311 | |||
| Opportunity subtotal × 1.0 | 0.460 | |||
| Combined downside | 3.771 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.431 |
Downside Rationale
The dominant downside of 5-Amino-1MQ is uncertainty, not a known acute danger. No intrinsic life-threatening signal has been found, so it does not reach the worst-case safety tier, but the compound has zero human safety data, an unconfirmed genetic-damage question tied to its chemical family, and a possible chronic cardiovascular cost from suppressing the metabolite 1-MNA (Domagala 2012). The people most exposed are those who buy from unregulated vendors and run it for months on faith. It is also banned in sport under WADA and sold without any quality oversight, which turns a pharmacological unknown into a practical one. Most of the risk here is a blindfold rather than a demonstrated harm, but for a compound you might take daily, that blindfold is the point.
Safety Risk (3.3/5.0): 5-Amino-1MQ has no human safety data, which is the core problem rather than any proven toxicity. Animal studies reported no acute organ damage at tested doses, and no anaphylaxis, organ-failure, or fatal signal exists, so it does not reach the worst-case safety tier. Two real concerns keep this elevated. First, its quinolinium chemical family includes known mutagens, and the lone no-genetic-damage claim is weakly sourced, so genotoxicity is unconfirmed rather than ruled out. Second, NNMT inhibition is methyl-sparing and trends anti-tumor (Palanichamy 2017), so the cancer-causing fear is likely backwards, but chronic effects on a healthy liver and brain are simply unstudied.
Side Effect Profile (3.0/5.0): The most common reported side effect of 5-Amino-1MQ is sleep disruption, especially at higher oral doses or when taken late in the day. Users also report jitteriness, early anxiety that often settles within two weeks, mild stomach upset, and harmless orange urine. One feature stands out: most people report no rise in heart rate or blood pressure, which separates it from caffeine-type stimulants. These reports are anecdotal and confounded by the other compounds people stack, but the sleep and stimulation pattern is consistent enough to plan around with morning-only dosing.
Financial Cost (3.7/5.0): 5-Amino-1MQ is expensive for an unproven compound. An 8-week oral cycle at 150 mg per day runs roughly $500 or more, while oral capsules from the cheaper sources land near $190 for 3,000 mg. Injectable use at genuinely effective doses climbs into triple digits per week, which is what pushes some users toward raw powder. You are paying clinical-grade prices for preclinical-grade certainty.
Time and Effort Burden (2.5/5.0): Day to day, 5-Amino-1MQ is low effort: an oral capsule once or twice daily, with optional cycling. The friction is elsewhere. Sourcing is genuinely hard, as Nick notes, and the injectable format adds reconstitution math that is a frequent source of error. For oral users the burden is minor, mostly remembering to dose in the morning and to cycle.
Opportunity Cost (3.0/5.0): Money and attention spent on 5-Amino-1MQ compete with interventions that have human evidence behind them, which is the real opportunity cost. For fat loss, diet, training, and proven tools will do more for most people. As a stack member it is generally compatible and even complements NAD+ precursors mechanistically, but the resources it consumes could buy more certain results elsewhere, especially for anyone who is not already lean and dialed in.
Dependency and Withdrawal (2.5/5.0): 5-Amino-1MQ shows no addictive potential, but some users report feeling tired or flat for a day or two after stopping, a mild functional rebound consistent with losing a stimulating effect. There is no craving and no withdrawal syndrome. The cycling people do is driven more by tolerance and cost than by dependence.
Reversibility (2.2/5.0): Effects of 5-Amino-1MQ appear to reverse cleanly on stopping, helped by a short half-life of about 6.9 hours, with no reported permanent changes. The one caveat that keeps this from scoring lower is the unconfirmed long-term genetic-damage question: if chronic use ever proved genotoxic, that harm would not be reversible. On current evidence, though, stopping returns you to baseline.
Is 5-Amino-1MQ worth it?
5-Amino-1MQ earns a Caution score because the mechanism and animal data are promising while the human evidence is absent and the supply chain is unregulated. It is reasonable to consider only if you are a lean health optimizer on a calorie deficit, you dose it orally at 50 to 150 mg, you source it carefully, and you treat it as an experiment you track rather than a proven tool. It is the wrong choice for anyone who wants evidence-backed results, competes in tested sport, or expects fat loss without diet. For most people, proven fundamentals like a real calorie deficit, resistance training, and sleep will move body composition further than this compound, which belongs in the experimental tier of a stack rather than the foundation. The score could rise quickly with a single clean human trial, or fall if genotoxicity is confirmed.
✅ Best for: Lean users on a calorie deficit who want a possible edge on fat oxidation and training energy and accept preclinical-grade certainty. People who specifically want the oral route and the felt energy effect, like Nick, who runs 50 to 100 mg as a pre-workout. Experienced self-experimenters who track their own biomarkers and subjective response. Stack-minded users pairing it with NAD+ precursors, where the mechanisms align. Anyone who can source a tested, accurately dosed product and is comfortable cycling it.
❌ Avoid if: You are pregnant, breastfeeding, or have an active or prior cancer, because there is no safety data for these groups. You compete in any tested sport, since 5-Amino-1MQ is WADA-banned under category S0. You have liver disease or are highly sensitive to stimulation or prone to insomnia. You want results backed by human trials, since none exist. You can only source it from consumer marketplaces like Amazon or eBay, where counterfeit and under-dosed product is a documented risk. You expect it to replace a calorie deficit for fat loss.
What is 5-Amino-1MQ best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Body Composition / Fat Loss Primary | 4.5 | Fat loss is the strongest endpoint: obese mice lost roughly 5% of body weight with over 30% smaller fat cells, driven by fat burning rather than appetite suppression (Neelakantan 2018). No human data exists, and anecdotal results concentrate in already-lean users on a calorie deficit. |
| ○ Muscle Growth / Hypertrophy Primary | 3.5 | Aged mice nearly doubled muscle-fiber size after injury (Neelakantan 2019), yet this is an aging-rescue pathway with no evidence it transfers to young, healthy users. |
| ○ Metabolic Health Primary | 3.3 | Glucose tolerance normalized in obese mice, but mostly with related NNMT inhibitors such as JBSNF-000088 (Kannt 2018), not 5-Amino-1MQ itself. |
| ○ Energy / Fatigue Primary | 3.5 | Energy is the most-reported subjective effect, and Nick feels it within 30 minutes, but no trial has measured it. The plausible route is restored NAD+ supporting cellular energy production. |
| ○ Methylation Support | 3.3 | NNMT inhibition spares the methyl donor SAM and raises the cell's methylation potential (Kraus 2014), but this is in-vitro and animal evidence only. |
| ○ Strength / Power | 3.0 | Grip strength rose about 40% in aged mice (Dimet-Wiley 2024), though other force measures did not change and no human data exists. |
| ○ Mitochondrial | 3.0 | By preserving NAD+, the compound plausibly supports mitochondrial function, though this is mechanistic and unmeasured in humans. |
| ○ Cellular Senescence | 3.0 | 5-Amino-1MQ reactivated senescent muscle stem cells in aged mice (Neelakantan 2019); no systemic senescence data in people. |
| ○ Recovery / Repair | 3.0 | Muscle regeneration accelerated in injured aged mice; recovery benefit in healthy trainees is untested. |
| ○ Endurance / Cardio | 3.0 | Running capacity improved when paired with exercise in aged mice (Dimet-Wiley 2024); unproven in humans. |
| ○ Blood Sugar / Glycemic Control | 3.0 | Blood-sugar improvements come mainly from related NNMT inhibitors in mice (Kannt 2018), not direct 5-Amino-1MQ trials. |
Frequently Asked Questions
What does 5-Amino-1MQ actually do?
5-Amino-1MQ blocks an enzyme called NNMT, which frees up nicotinamide to rebuild NAD+ and preserves the cell's methyl-group supply. In obese mice this shrank fat cells and lowered body weight (Neelakantan 2018), and in aged mice it reactivated tired muscle stem cells (Neelakantan 2019). The energy lift many users feel likely traces to that restored NAD+, though no study has measured it. All of this is preclinical, and no human trial has confirmed these effects.
How much 5-Amino-1MQ should I take, and when?
There is no validated human dose for 5-Amino-1MQ. Community and practitioner convention is 50 to 150 mg per day taken orally, usually in the morning because it can disrupt sleep later. Most people cycle 4 to 8 weeks, then take a 1 to 2 week break. The rat pharmacokinetic study supports oral dosing, with about 38% bioavailability and a 6.9 hour half-life (Awosemo 2021).
What does the human evidence on 5-Amino-1MQ show?
There is no human evidence for 5-Amino-1MQ. ClinicalTrials.gov lists zero registered trials, and there are no published human safety, dosing, or efficacy studies. Every result comes from mice, rats, or cell cultures, and most of the in-vivo work traces to a single research group. Vendor claims of registered Phase 2 trials are not backed by any public registry, so treat any human-efficacy claim you see as marketing rather than data.
Is 5-Amino-1MQ safe?
Nobody knows the long-term safety of 5-Amino-1MQ, because there is no human data. Animal studies showed no acute organ toxicity at tested doses, and no intrinsic life-threatening signal has been found. The real concerns are the total absence of human safety records, an unconfirmed question about genetic-damage potential in its chemical family, and a grey-market supply chain with no quality oversight. Common reported effects are sleep disruption, jitteriness, and mild stomach upset.
Who should avoid 5-Amino-1MQ?
Avoid 5-Amino-1MQ if you are pregnant or breastfeeding, have an active or prior cancer, or have liver disease, because there is no safety data for any of these groups. Competitive athletes should also avoid it: it falls under WADA category S0 and will trigger a doping violation. Anyone sensitive to stimulation or prone to insomnia should be careful, since energizing effects and sleep disruption are the most common complaints.
Oral or injectable 5-Amino-1MQ: which is better?
Oral is the route that makes pharmacological sense for 5-Amino-1MQ. It is a small molecule with documented oral absorption (Awosemo 2021), and the human convention of 50 to 150 mg per day relies on that. Many injectable products contain only 5 to 60 mg total, and microgram-per-day injection protocols are widely reported as doing nothing. If you use it at all, oral capsules remove the guesswork and the reconstitution math.
How fast does 5-Amino-1MQ work?
Users typically feel the energy effect of 5-Amino-1MQ within 30 to 90 minutes of an oral dose. Body-composition changes, when they happen, are reported over 4 to 8 weeks of daily use, usually alongside a calorie deficit. None of these timelines come from a controlled trial. They reflect community reports and personal experience, which are heavily confounded by the other compounds people stack with it.
Does 5-Amino-1MQ actually help you lose fat?
Fat loss is the best-supported use for 5-Amino-1MQ, but the support is preclinical. Obese mice lost roughly 5% of body weight with over 30% smaller fat cells, driven by increased fat burning rather than appetite suppression (Neelakantan 2018). Human results are anecdotal and strongest in already-lean people on a calorie deficit. It is not a substitute for diet, and many users who expected dramatic fat loss were disappointed.
What could change 5-Amino-1MQ's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Two findings would move the 5-Amino-1MQ score the most, in opposite directions. The fastest upward mover would be human data: a single well-designed oral trial that confirms fat loss would lift both Efficacy and Evidence Quality and could push the score into Neutral or higher. Because the Evidence Quality score sits near the floor at 1.8, it has the most room to rise, so efficacy and evidence are the dimensions that would change first. The fastest downward mover would be a confirmed safety problem, especially genotoxicity, which would raise the Safety and Reversibility penalties and drag the score toward Skip. The scenarios below show recalculated scores using the same scoring formula, with the dimension changes that drive each one, and none of them rest on speculation beyond the single change named.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A Phase 2 human trial confirms oral fat loss | Evidence 1.8 to 3.5, Efficacy 3.0 to 3.8 | 4.9 / 10 ⚖️ Neutral |
| Independent labs replicate the muscle and fat findings | Evidence 1.8 to 2.8, Bioindividuality 2.5 to 3.0 | 4.6 / 10 ⚖️ Neutral |
| Long-term human safety data emerges clean | Safety 3.3 to 2.5 | 4.6 / 10 ⚖️ Neutral |
| A regulated, quality-tested oral product reaches market | Safety 3.3 to 3.0, Cost 3.7 to 3.0 | 4.4 / 10 ⚠️ Caution |
| A human trial shows no meaningful effect | Efficacy 3.0 to 1.5, Evidence 1.8 to 2.5 | 4.1 / 10 ⚠️ Caution |
| Genotoxicity is confirmed in the quinolinium scaffold | Safety 3.3 to 4.0, Reversibility 2.2 to 3.5 | 3.6 / 10 ⚠️ Caution |
Key Evidence Sources
- Neelakantan 2018, Biochem Pharmacol: 5-Amino-1MQ reversed high-fat-diet obesity in mice. Body weight and fat-cell size fell; effect via fat burning, not appetite
- Neelakantan 2019, Biochem Pharmacol: 5-Amino-1MQ activated senescent muscle stem cells in aged mice. Roughly doubled muscle-fiber size and raised peak torque after injury
- Dimet-Wiley 2024, Sci Rep: NNMT inhibition mimicked and boosted exercise in aged mice. Grip strength rose about 40%; some force measures unchanged
- Sampson 2021, Sci Rep: NNMT inhibition plus reduced-calorie diet normalized body composition in obese mice. Combination outperformed diet alone
- Awosemo 2021, J Pharm Biomed Anal: pharmacokinetics of 5-Amino-1MQ in rats. Oral bioavailability 38.4%, oral half-life 6.9 hours (rat)
- Kraus 2014, Nature: NNMT knockdown protected against diet-induced obesity. Established the NNMT, NAD+, and methyl-pool mechanism
- Kannt 2018, Sci Rep: a small-molecule NNMT inhibitor improved metabolic disease in mice. Glucose tolerance normalized with JBSNF-000088, a related inhibitor
- Schmeisser 2013, Nat Chem Biol: 1-MNA, the metabolite NNMT produces, can extend lifespan in C. elegans. Complicates the simple NNMT-inhibition-equals-longevity story
- Przyborowski 2015, PLoS One: 1-MNA improved exercise capacity and endothelial function in diabetic mice. Suggests suppressing 1-MNA could remove a benefit
- Domagala 2012, Hypertension: 1-MNA produced nitric-oxide-mediated vasorelaxation in human blood vessels. Cardiovascular caution for chronic NNMT inhibition
- Palanichamy 2017, Clin Cancer Res: NNMT silencing reactivated tumor-suppressor PP2A. NNMT inhibition trends anti-tumor, not carcinogenic
- Eckert 2019, Nature: NNMT is a master metabolic regulator of cancer-associated fibroblasts. Confirms the methyl-pool depletion mechanism
- Pissios 2017, Trends Endocrinol Metab: review of NNMT beyond vitamin B3 clearance. Background on NNMT biology
- Sun 2024, Front Pharmacol: NNMT as a therapeutic target for metabolic syndrome. Narrative review of the target, not 5-Amino-1MQ efficacy
- Puleo 2026, Trends Pharmacol Sci: emerging opportunities for NNMT inhibitor clinical translation. Independent groups judge NNMT a credible, drug-like target
What does the evidence say about 5-Amino-1MQ?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Limited
Citations: Neelakantan 2018, Neelakantan 2019, Dimet-Wiley 2024, Kraus 2014, Awosemo 2021
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c During | Expected Down
- Fasting Insulin During | Expected Watch
- Lipid Panel During | Expected Down
- Homocysteine During | Expected Down
- Alt Ast Pre | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Sleep During | Expected Watch | Secondary
- Body During | Expected Up | Secondary
- Drive During | Expected Up | Tertiary
Subjective Signals (Daily Voice Card)
- Jitteriness or restlessness Scale 1-5 | During | Expected Watch
- Sleep onset difficulty Scale 1-5 | During | Expected Watch
- Training energy and pump Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Heart palpitations, severe anxiety, or blood pressure spikes
- Persistent insomnia despite morning-only dosing
- Any product that acts like a diuretic or causes unexpected symptoms (possible counterfeit)
- Pregnancy, breastfeeding, or active or prior cancer: stop and consult a medical professional
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.655 − 2.431 = -0.776
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.776 / 7) × 5 = 4.4 / 10
